NCT02001623 2021-12-29Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsSeagen Inc.Phase 1/2 Completed195 enrolled 51 charts
NCT03245736 2021-11-04Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.Seagen Inc.Phase 2 Completed5 enrolled 8 charts